Licensing Agreements

Partnerships Drug Development Financial Transactions Strategic Partnerships Co-Marketing Generic Production Lupin Pharmaceuticals Global Collaborations Market Authorization Market Competition

3 ARTICLES

2mo ago

Spero Licenses Innovent’s Anti‑CD40L Antibody Outside Greater China in Up to $1.1 Billion Deal

The agreement gives Innovent immediate cash plus milestone and royalty upside while positioning Spero to build an immunology program and advance mid‑stage trials next year.

5 ARTICLES

2mo ago

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

4 ARTICLES

3mo ago

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

3 ARTICLES

6mo ago

Brazil Approves Xcopri for Drug-Resistant Focal Epilepsy as Eurofarma Secures Registration

3 ARTICLES

6mo ago

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

9 ARTICLES

7mo ago

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

3 ARTICLES

7mo ago

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

4 ARTICLES

8mo ago

Novartis Licenses SciNeuro’s Brain‑Shuttle Alzheimer’s Antibodies in Deal Worth Up to $1.7 Billion

8 ARTICLES

9mo ago

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

3 ARTICLES

9mo ago

Dr Reddy’s, Immutep Sign Efti Licensing Deal Covering Markets Outside North America, Europe, Japan and Greater China

9 ARTICLES

11mo ago

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

5 ARTICLES

11mo ago

Zenas BioPharma Licenses InnoCare’s Orelabrutinib in Autoimmune Deal Topping $2 Billion

4 ARTICLES

11mo ago

Glenmark Strikes Exclusive Deal With Hengrui for Next‑Gen HER2 ADC, Paying $18 Million Upfront

8 ARTICLES

last yr.

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

3 ARTICLES

last yr.

AbbVie Enters Obesity Drug Market with $2.2 Billion Licensing Deal

Licensing Agreements

Spero Licenses Innovent’s Anti‑CD40L Antibody Outside Greater China in Up to $1.1 Billion Deal

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

Brazil Approves Xcopri for Drug-Resistant Focal Epilepsy as Eurofarma Secures Registration

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

Novartis Licenses SciNeuro’s Brain‑Shuttle Alzheimer’s Antibodies in Deal Worth Up to $1.7 Billion

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Dr Reddy’s, Immutep Sign Efti Licensing Deal Covering Markets Outside North America, Europe, Japan and Greater China

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Zenas BioPharma Licenses InnoCare’s Orelabrutinib in Autoimmune Deal Topping $2 Billion

Glenmark Strikes Exclusive Deal With Hengrui for Next‑Gen HER2 ADC, Paying $18 Million Upfront

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

AbbVie Enters Obesity Drug Market with $2.2 Billion Licensing Deal

Never miss stories about

Licensing Agreements